We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Sekisui Diagnostics

For 40 years SEKISUI Diagnostics has been committed to providing innovative medical diagnostics to physicians and lab... read more Featured Products: More products

Download Mobile App





Sekisui Diagnostics Displays POC Rapid Diagnostics and Clinical Chemistry Reagents at AACC 2021

By LabMedica International staff writers
Posted on 28 Sep 2021
Print article
Image: Sekisui Diagnostics Displays POC Rapid Diagnostics and Clinical Chemistry Reagents at AACC 2021 (Photo courtesy of SEKISUI Diagnostics)
Image: Sekisui Diagnostics Displays POC Rapid Diagnostics and Clinical Chemistry Reagents at AACC 2021 (Photo courtesy of SEKISUI Diagnostics)

SEKISUI Diagnostics (Burlington, MA, USA) displayed its point-of-care rapid diagnostics and clinical chemistry reagents at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

This year’s 2021 AACC was held in partnership with the Canadian Society of Clinical Chemists (CSCC) at the Georgia World Congress Center in Atlanta, September 26-30. SEKISUI Diagnostics delivers differentiated products, instrument systems, and services that support the improvement of patient care worldwide. The company is a recognized leader in the development, manufacture, and supply of innovative clinical chemistry reagents and systems that enhance the clinical chemistry laboratory function. Over 1.7 billion tests are performed each year using the company’s products. With a broad line of >65 reagents including cardiovascular, diabetes, renal, liver, therapeutic drug, and specialty assays, SEKISUI is well-poised to meet individual needs.

At AACC 2021, SEKISUI displayed its OSOM rapid diagnostics that offers a variety of family and women’s health products, and services. These diagnostic tests allow healthcare professionals to cost effectively diagnose at the point-of-care in one visit, thus reducing labor and follow-up time while increasing patient satisfaction. The company also demonstrated its Acucy System that provides clinicians with flexibility in workflow and accurate, standardized results for improved patient care.

Also on display was SEKISUI’s FastPack IP System which is a fully automated quantitative immunoassay analyzer designed for use in any size physician office laboratory and provides results in 12 minutes or less with the push of a button. Offering real-time testing with a simple three-step process, the system enables healthcare professionals to diagnose, monitor, and adjust therapy in one patient visit.

Related Links:
SEKISUI Diagnostics 

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Unstirred Waterbath
HumAqua 5
New
Cytomegalovirus Test
NovaLisa Cytomegalovirus (CMV) IgG Test

Print article
ADLM

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Molecular Diagnostics

view channel
Image: Health Canada has approved SPINEstat, a first-in-class diagnostic blood test for axSpA, as a Class II medical device (Photo courtesy of Augurex)

First-in-Class Diagnostic Blood Test Detects Axial Spondyloarthritis

Axial spondyloarthritis (axSpA) is a chronic inflammatory autoimmune condition that typically affects individuals during their most productive years, with symptoms often emerging before the age of 45.... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.